The Global Peptide Therapeutics Market, by Type (Branded Peptide and Generic Peptide), by Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, and Others), By Route of Administration (Oral Administration, Parenteral Administration, and Others), was valued US$ 22.5 billion in 2018, and is projected to exhibit a CAGR of 9.1% over the forecast period (2018 - 2026) as highlighted in a new report published by Coherent Market Insights.
Peptide therapeutics have wide range of applications in medicine and biotechnology and therapeutic peptide research field. Peptide therapeutics are majorly used in the cancer treatment and type 2 diabetes mellitus (T2DM) treatment. According to the Drug Discovery Today, January 2015 data findings, novel peptide drug class: glucagon-like peptide-1 (GLP-1) agonists; indicated for the treatment of type 2 diabetes mellitus (T2DM), shows lucrative market growth, as Victoza from Novo Nordisk, is the most prominent member of the class, reaching blockbuster status. Moreover, main area currently driving the growth of peptide therapeutics drugs adoption are metabolic diseases and cancer treatment. Furthermore, peptide therapeutics are in clinical testing for infectious diseases and inflammation.
Key players in the peptide therapeutic market are engaged in expanding market share through new product launches and regulatory approval. For instance, in March 2016, Eli Lilly and Company introduced anti-diabetes drug Trulicity (dulaglutide) in India. Trulicity (dulaglutide) is once-a- week non-insulin injectable belonging to class of drugs called glucagon-like peptide (GLP-1) receptor agonist, which helps the body to release its own insulin after the intake of food. In July 2016, U.S. Food and Drug Administration (FDA), approved Sanofi-Aventis’s Adlyxin (lixisenatide), a once-daily injection to improve glycemic control (blood sugar levels), along with diet and exercise, in adults with type 2 diabetes.
Browse 26 Market Data Tables and 45 Figures spread through 189 Pages and in-depth TOC on "Peptide Therapeutics Market, by Type (Branded Peptide and Generic Peptide), by Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease and Others), By Route of Administration (Oral Administration, Parenteral Administration, and Others) - Global Forecast to 2026"
To know the latest trends and insights related to peptide therapeutics market, click the link below:
Peptide therapeutics market is projected to witness lucrative growth over the forecast period, owing to the various in-organic growth strategies implemented by key manufacturing players in this market. For instance, in July 2012, Amgen Inc. completed the acquisition of KAI Pharmaceuticals, Inc. for a deal value of US$ 315 million. During the acquisition, KAI Pharmaceuticals had a peptide product in development stage: KAI-4169, which is indicated for the treatment of Secondary Hyperparathyroidism (SHPT) in patients with Chronic Kidney Disease (CKD) who are on dialysis and is in currently in phase 2 trials. Moreover, this acquisition allowed Amgen to acquire worldwide rights of KAI-4169, excluding Japan.
Furthermore, in September 2015, PeptiDream Inc. developed a multi-target discovery and optimization collaboration with Sanofi S.A. Under this agreement, PeptiDream will use their proprietary Peptide Discovery Platform System (PDPS) technology to generate macrocyclic/constrained peptides against multiple targets of interest selected by Sanofi S.A. Furthermore, Sanofi will have the right to develop and commercialize all therapeutic peptides resulting from the collaboration.
In December 2017, Entrega collaborated with Eli Lilly and Company to make advancement in Entrega’s proprietary peptide delivery technology. Under the agreement, Entrega will receive the US$ 5 million in equity and research in funding from Eli Lilly to investigate the application of Entrega’s peptide delivery technology to certain Lilly products and their therapeutic candidates.
Key takeaways of the Peptide Therapeutics Market:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Email: [email protected]
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.